Last reviewed · How we verify
Both deferoxamine mesylate and colchicine
This combination uses deferoxamine to chelate iron and reduce oxidative stress, while colchicine suppresses inflammatory responses, together targeting myocardial injury and fibrosis in heart failure.
This combination uses deferoxamine to chelate iron and reduce oxidative stress, while colchicine suppresses inflammatory responses, together targeting myocardial injury and fibrosis in heart failure. Used for Acute heart failure (Phase 3 investigation).
At a glance
| Generic name | Both deferoxamine mesylate and colchicine |
|---|---|
| Sponsor | The George Institute |
| Drug class | Iron chelator + anti-inflammatory combination |
| Target | Labile iron (deferoxamine); microtubule polymerization and NLRP3 inflammasome (colchicine) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Deferoxamine mesylate is an iron chelator that reduces labile iron and associated oxidative damage in cardiac tissue. Colchicine is an anti-inflammatory agent that inhibits microtubule polymerization and reduces inflammasome activation. Together, they aim to reduce iron-mediated oxidative stress and inflammation in acute heart failure, potentially improving cardiac function and reducing mortality.
Approved indications
- Acute heart failure (Phase 3 investigation)
Common side effects
- Diarrhea (colchicine)
- Nausea
- Abdominal pain
- Injection site reactions (deferoxamine)
- Hypotension
Key clinical trials
- The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL (PHASE3)
- ACT-GLOBAL Adaptive Platform Trial for Stroke (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: